Vortioxetine hydrobromide (BioDeep_00000753128)

   


代谢物信息卡片


Vortioxetine (Lu AA21004) HBr

化学式: C18H23BrN2S (378.0765218)
中文名称: 氢溴酸沃替西汀
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C.Br
InChI: 1H

描述信息

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
D049990 - Membrane Transport Modulators
Vortioxetine hydrobromide is a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT with Ki values of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively.

同义名列表

4 个代谢物同义名

Vortioxetine (Lu AA21004) HBr; Vortioxetine hydrobromide; Lu AA21004 (hydrobromide); Vortioxetine (hydrobromide)



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yasamin Khoshnavaz, Erknaz Ecehan Erk, Guangli Li, Mohammad Mehmandoust, Nevin Erk. Green synthesis of Au@g-C3N4 nanocomposite using Hyssopus officinalis extract and its sensing application for vortioxetine determination. Environmental science and pollution research international. 2023 Jul; 30(33):80085-80093. doi: 10.1007/s11356-023-28040-8. [PMID: 37289391]
  • Caroline Hermann Nodari, Natália Dalanhol De Quadros, Raquel Chiarentin, Francini Pereira Da Silva, Fernando Dal Pont Morisso, Mariele Feiffer Charão, Juliane Deise Fleck, Cristiane Bastos De Mattos, Andresa Heemann Betti, Simone Gasparin Verza. Vortioxetine liposomes as a novel alternative to improve drug stability under stress conditions: toxicity studies and evaluation of antidepressant-like effect. Pharmacological reports : PR. 2022 Oct; 74(5):969-981. doi: 10.1007/s43440-022-00412-w. [PMID: 36076124]
  • Trine Frederiksen, Robert L Smith, Marin M Jukic, Espen Molden. Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching: A Retrospective, Naturalistic Cohort Study Using Therapeutic Drug Monitoring Data From 640 Patients. Journal of clinical psychopharmacology. 2022 Jul; 42(4):396-399. doi: 10.1097/jcp.0000000000001563. [PMID: 35703273]
  • Samantha Smith, Jordan Sergio, Michael Coyle, Kayla Elder, Ashley Centner, Sophie Cohen, Michelle Terry, Natalie Lipari, John Glinski, Emily Wheelis, Carla Budrow, Christopher Bishop. The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats. Psychopharmacology. 2022 Jul; 239(7):2119-2132. doi: 10.1007/s00213-022-06078-9. [PMID: 35275226]
  • Hemant Suryavanshi, Raju D Chaudhari, Vishakha Patil, Swapan Majumdar, Sudhan Debnath, Goutam Biswas. Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2022 Jun; 30(1):139-152. doi: 10.1007/s40199-022-00441-z. [PMID: 35508799]
  • Majid D Farahani, Tanos C C França, Saba Alapour, Fatma Shahout, Richard Boulon, Mustapha Iddir, Michael Maddalena, Yann Ayotte, Steven R LaPlante. Jumping from Fragment to Drug via Smart Scaffolds. ChemMedChem. 2022 05; 17(10):e202200092. doi: 10.1002/cmdc.202200092. [PMID: 35298873]
  • Takashi Shiroyama, Kouji Fukuyama, Motohiro Okada. Distinct Effects of Escitalopram and Vortioxetine on Astroglial L-Glutamate Release Associated with Connexin43. International journal of molecular sciences. 2021 Sep; 22(18):. doi: 10.3390/ijms221810013. [PMID: 34576176]
  • Xianwei Mo, Yuanyuan Li, Xinying Zhu, Xiaolei Li, Haiyan Zhou, Xinzhou Bi, Jing Li. Vortioxetine Derivatives with Amino Acid as Promoiety: Synthesis, Activity, Stability and Preliminary Pharmacokinetic Study. Journal of pharmaceutical sciences. 2021 08; 110(8):3011-3019. doi: 10.1016/j.xphs.2021.04.011. [PMID: 33891948]
  • Marina Sagud, Matea Nikolac Perkovic, Anja Dvojkovic, Nenad Jaksic, Bjanka Vuksan-Cusa, Maja Zivkovic, Zorana Kusevic, Alma Mihaljevic-Peles, Nela Pivac. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram. Psychopharmacology. 2021 Jun; 238(6):1575-1584. doi: 10.1007/s00213-021-05790-2. [PMID: 33560444]
  • Andrea Fagiolini, Ioana Florea, Henrik Loft, Michael Cronquist Christensen. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment. Journal of affective disorders. 2021 03; 283(?):472-479. doi: 10.1016/j.jad.2020.11.106. [PMID: 33516560]
  • Anja Dvojkovic, Matea Nikolac Perkovic, Marina Sagud, Gordana Nedic Erjavec, Alma Mihaljevic Peles, Dubravka Svob Strac, Bjanka Vuksan Cusa, Lucija Tudor, Zorana Kusevic, Marcela Konjevod, Maja Zivkovic, Sasa Jevtovic, Nela Pivac. Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients. Progress in neuro-psychopharmacology & biological psychiatry. 2021 03; 105(?):110016. doi: 10.1016/j.pnpbp.2020.110016. [PMID: 32534176]
  • Motohiro Okada, Ryusuke Matsumoto, Yoshimasa Yamamoto, Kouji Fukuyama. Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor. International journal of molecular sciences. 2021 Jan; 22(3):. doi: 10.3390/ijms22031351. [PMID: 33572981]
  • Trine Frederiksen, Johan Areberg, Ellen Schmidt, Tore Bjerregaard Stage, Kim Brøsen. Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine. Clinical pharmacology and therapeutics. 2021 01; 109(1):150-159. doi: 10.1002/cpt.1972. [PMID: 32599653]
  • Qiong Wang, Zhe Chen, Dingwen Chen, Shunbin Luo, Lingping Xie. Simultaneous quantification of vortioxetine, fluoxetine and their metabolites in rat plasma by UPLC-MS/MS. Biomedical chromatography : BMC. 2020 Dec; 34(12):e4960. doi: 10.1002/bmc.4960. [PMID: 32729624]
  • Elmars Rancans, Janos Zambori, Mads Dalsgaard, Corine Baayen, Johan Areberg, Anders Ettrup, Ioana Florea. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study. International clinical psychopharmacology. 2020 11; 35(6):305-312. doi: 10.1097/yic.0000000000000326. [PMID: 32784346]
  • Mater H Mahnashi. Synthesis of three-dimensional nickel ferrite nanospheres decorated activated graphite nanoplatelets for electrochemical detection of vortioxetine with pharmacokinetic insights in human volunteers. Mikrochimica acta. 2020 08; 187(9):519. doi: 10.1007/s00604-020-04523-0. [PMID: 32852618]
  • Eric J Lenze, Angela Stevens, Jill D Waring, Vy T Pham, Rita Haddad, Josh Shimony, J Philip Miller, Christopher R Bowie. Augmenting Computerized Cognitive Training With Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial. The American journal of psychiatry. 2020 06; 177(6):548-555. doi: 10.1176/appi.ajp.2019.19050561. [PMID: 32212856]
  • Anna Petruczynik, Karol Wróblewski, Krzysztof Wojtanowski, Tomasz Mroczek, Dariusz Juchnowicz, Hanna Karakuła-Juchnowicz, Tomasz Tuzimski. Comparison of Various Chromatographic Systems for Identification of Vortioxetine in Bulk Drug Substance, Human Serum, Saliva, and Urine Samples by HPLC-DAD and LC-QTOF-MS. Molecules (Basel, Switzerland). 2020 May; 25(11):. doi: 10.3390/molecules25112483. [PMID: 32471141]
  • Oleg A Levada, Alexandra S Troyan, Irina Y Pinchuk. Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study. BMC psychiatry. 2020 05; 20(1):208. doi: 10.1186/s12888-020-02636-7. [PMID: 32384884]
  • Martin Kertys, Michaela Krivosova, Igor Ondrejka, Igor Hrtanek, Ingrid Tonhajzerova, Juraj Mokry. Simultaneous determination of fluoxetine, venlafaxine, vortioxetine and their active metabolites in human plasma by LC-MS/MS using one-step sample preparation procedure. Journal of pharmaceutical and biomedical analysis. 2020 Mar; 181(?):113098. doi: 10.1016/j.jpba.2020.113098. [PMID: 31978643]
  • Yingyue Yi, Guanghui Ren, Ming Zheng, Di Zhao, Ning Li, Xijng Chen, Yang Lu. Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2020 Feb; 1138(?):121955. doi: 10.1016/j.jchromb.2019.121955. [PMID: 31911203]
  • Xia Xiao, Conghui Wang, De Chang, Ying Wang, Xiaojing Dong, Tao Jiao, Zhendong Zhao, Lili Ren, Charles S Dela Cruz, Lokesh Sharma, Xiaobo Lei, Jianwei Wang. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. Frontiers in immunology. 2020; 11(?):586572. doi: 10.3389/fimmu.2020.586572. [PMID: 33324406]
  • Sacha Uljon, Yachana Kataria, James G Flood. Vortioxetine use may cause false positive immunoassay results for urine methadone. Clinica chimica acta; international journal of clinical chemistry. 2019 Dec; 499(?):1-3. doi: 10.1016/j.cca.2019.08.026. [PMID: 31469980]
  • Jia Miao, Gang Wang, Jie Hou, Johan Areberg, Yan Zhao, Astrid-Maria Højer, Anders Ettrup. Pharmacokinetics and Safety of Vortioxetine in the Chinese Population. Advances in therapy. 2019 11; 36(11):3134-3146. doi: 10.1007/s12325-019-01092-4. [PMID: 31552551]
  • Bing Cao, Caroline Park, Joshua D Rosenblat, Yan Chen, Michelle Iacobucci, Mehala Subramaniapillai, Rodrigo B Mansur, Hannah Zuckerman, Yena Lee, Roger S McIntyre. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial. Journal of psychopharmacology (Oxford, England). 2019 11; 33(11):1388-1394. doi: 10.1177/0269881119874485. [PMID: 31530216]
  • Mehala Subramaniapillai, Rodrigo B Mansur, Hannah Zuckerman, Caroline Park, Yena Lee, Michelle Iacobucci, Bing Cao, Roger Ho, Kangguang Lin, Lee Phan, Roger S McIntyre. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine. Comprehensive psychiatry. 2019 10; 94(?):152113. doi: 10.1016/j.comppsych.2019.07.006. [PMID: 31404802]
  • Guanyun Yan, Meng Zhang, Yafang Liu, Mei Yin. Efficacy of vortioxetine combined cognitive behaviour intervention therapy on brain-derived neurotrophic factor level on depressive patients. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society. 2019 Sep; 19(5):475-481. doi: 10.1111/psyg.12426. [PMID: 30780196]
  • Eduard Vieta, Ioana Florea, Simon Nitschky Schmidt, Johan Areberg, Anders Ettrup. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study. International clinical psychopharmacology. 2019 07; 34(4):153-160. doi: 10.1097/yic.0000000000000271. [PMID: 31094901]
  • Kathryn Kieran. Three Recent Cases of Likely Methadone Cross-Reactivity With Vortioxetine. Journal of the American Psychiatric Nurses Association. 2019 May; 25(3):170. doi: 10.1177/1078390318792601. [PMID: 31117909]
  • Derek Spieler, Christian Namendorf, Tamara Namendorf, Manfred Uhr. abcb1ab p-glycoprotein is involved in the uptake of the novel antidepressant vortioxetine into the brain of mice. Journal of psychiatric research. 2019 02; 109(?):48-51. doi: 10.1016/j.jpsychires.2018.11.009. [PMID: 30476727]
  • Su Guan, Yake Zou, Bingjie Jia, Lvying Wu, Zhicheng Yang, Fang Yuan, Lei Zhang. Pharmacokinetic and metabolic studies of Vortioxetine in rats using ultra high performance liquid chromatography with tandem mass spectrometry. Journal of separation science. 2018 Dec; 41(24):4469-4479. doi: 10.1002/jssc.201800607. [PMID: 30354005]
  • Grace Chen, George G Nomikos, John Affinito, William Jacobson, Zhen Zhao, Shining Wang, Jinhui Xie. Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine. Clinical pharmacology in drug development. 2018 11; 7(8):880-888. doi: 10.1002/cpdd.577. [PMID: 29920978]
  • Grace Chen, Astrid-Maria Højer, Johan Areberg, George Nomikos. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clinical pharmacokinetics. 2018 06; 57(6):673-686. doi: 10.1007/s40262-017-0612-7. [PMID: 29189941]
  • David J Greenblatt, Jerold S Harmatz, Christina R Chow. Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. Journal of clinical psychopharmacology. 2018 Jun; 38(3):172-179. doi: 10.1097/jcp.0000000000000861. [PMID: 29596146]
  • N Hlavacova, Y Li, A Pehrson, C Sanchez, I Bermudez, A Csanova, D Jezova, M Franklin. Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. Progress in neuro-psychopharmacology & biological psychiatry. 2018 03; 82(?):332-338. doi: 10.1016/j.pnpbp.2017.07.008. [PMID: 29269186]
  • Kumi Matsuno, Koki Nakamura, Yutaka Aritomi, Akira Nishimura. Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults. Clinical pharmacology in drug development. 2018 03; 7(3):319-331. doi: 10.1002/cpdd.381. [PMID: 28941196]
  • Michael Cronquist Christensen, Henrik Loft, Roger S McIntyre. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. Journal of affective disorders. 2018 02; 227(?):787-794. doi: 10.1016/j.jad.2017.11.081. [PMID: 29689693]
  • Maria Talmon, Silvia Rossi, Anna Pastore, Carlo Ignazio Cattaneo, Sandra Brunelleschi, Luigia Grazia Fresu. Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. British journal of pharmacology. 2018 01; 175(1):113-124. doi: 10.1111/bph.14074. [PMID: 29057467]
  • Robert L Findling, Adelaide S Robb, Melissa DelBello, Michael Huss, Nora McNamara, Elias Sarkis, Russell Scheffer, Lis H Poulsen, Grace Chen, Ole Michael Lemming, Johan Areberg, Philippe Auby. Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients. Journal of child and adolescent psychopharmacology. 2017 Aug; 27(6):526-534. doi: 10.1089/cap.2016.0155. [PMID: 28333546]
  • Amanda Eskelund, Yan Li, David P Budac, Heidi K Müller, Maria Gulinello, Connie Sanchez, Gregers Wegener. Drugs with antidepressant properties affect tryptophan metabolites differently in rodent models with depression-like behavior. Journal of neurochemistry. 2017 07; 142(1):118-131. doi: 10.1111/jnc.14043. [PMID: 28407315]
  • Alex G Nackenoff, Linda D Simmler, Nicole L Baganz, Alan L Pehrson, Connie Sánchez, Randy D Blakely. Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine As Revealed Using the SERT Met172 Mouse. ACS chemical neuroscience. 2017 05; 8(5):1092-1100. doi: 10.1021/acschemneuro.7b00038. [PMID: 28272863]
  • Roger S McIntyre, Ioana Florea, Brigitte Tonnoir, Henrik Loft, Raymond W Lam, Michael Cronquist Christensen. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. The Journal of clinical psychiatry. 2017 01; 78(1):115-121. doi: 10.4088/jcp.16m10744. [PMID: 27780334]
  • Yi Huang, Shuangli Zheng, Yongyang Pan, Tao Li, Zhi-Sheng Xu, Meng-Meng Shao. Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. Journal of pharmaceutical and biomedical analysis. 2016 Sep; 128(?):184-190. doi: 10.1016/j.jpba.2016.05.029. [PMID: 27262994]
  • Grace Chen, George G Nomikos, John Affinito, Zhen Zhao. Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium. Clinical pharmacokinetics. 2016 09; 55(9):1115-27. doi: 10.1007/s40262-016-0389-0. [PMID: 27048210]
  • Marina Sagud, Matea Nikolac Perkovic, Bjanka Vuksan-Cusa, Anja Maravic, Dubravka Svob Strac, Alma Mihaljevic Peles, Maja Zivkovic, Zorana Kusevic, Nela Pivac. A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Psychopharmacology. 2016 Sep; 233(17):3259-67. doi: 10.1007/s00213-016-4364-0. [PMID: 27356518]
  • Christoffer Bundgaard, Elin Eneberg, Connie Sánchez. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo. Neuropharmacology. 2016 Apr; 103(?):104-11. doi: 10.1016/j.neuropharm.2015.12.009. [PMID: 26700248]
  • Jacob Andersen, Lucy Kate Ladefoged, Danyang Wang, Trine N Bjerre Kristensen, Benny Bang-Andersen, Anders S Kristensen, Birgit Schiøtt, Kristian Strømgaard. Binding of the multimodal antidepressant drug vortioxetine to the human serotonin transporter. ACS chemical neuroscience. 2015 Nov; 6(11):1892-900. doi: 10.1021/acschemneuro.5b00225. [PMID: 26389667]
  • Sue Wilson, Astrid-Maria Højer, Jeppe Buchberg, Johan Areberg, David J Nutt. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. Journal of psychopharmacology (Oxford, England). 2015 Oct; 29(10):1085-91. doi: 10.1177/0269881115599387. [PMID: 26253622]
  • Edoardo Spina, Vincenza Santoro. Drug interactions with vortioxetine, a new multimodal antidepressant. Rivista di psichiatria. 2015 Sep; 50(5):210-5. doi: 10.1708/2040.22160. [PMID: 26489070]
  • Er-min Gu, Chengke Huang, Bingqing Liang, Lingjing Yuan, Tian Lan, Guoxin Hu, Hongyu Zhou. An UPLC-MS/MS method for the quantitation of vortioxetine in rat plasma: Application to a pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2015 Aug; 997(?):70-4. doi: 10.1016/j.jchromb.2015.05.010. [PMID: 26094207]
  • Yan Li, Aicha Abdourahman, Joseph A Tamm, Alan L Pehrson, Connie Sánchez, Maria Gulinello. Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice. Pharmacology, biochemistry, and behavior. 2015 Aug; 135(?):70-82. doi: 10.1016/j.pbb.2015.05.013. [PMID: 26046533]
  • Atul R Mahableshwarkar, John Zajecka, William Jacobson, Yinzhong Chen, Richard S E Keefe. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2015 Jul; 40(8):2025-37. doi: 10.1038/npp.2015.52. [PMID: 25687662]
  • Stephen M Stahl. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS spectrums. 2015 Apr; 20(2):93-7. doi: 10.1017/s1092852915000139. [PMID: 25831967]
  • Morten A Kall, Morten Rohde, Martin Jørgensen. Quantitative determination of the antidepressant vortioxetine and its major human metabolite in plasma. Bioanalysis. 2015; 7(22):2881-94. doi: 10.4155/bio.15.207. [PMID: 26571228]
  • Connie Sanchez, Karen E Asin, Francesc Artigas. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacology & therapeutics. 2015 Jan; 145(?):43-57. doi: 10.1016/j.pharmthera.2014.07.001. [PMID: 25016186]
  • Alan F Schatzberg, Pierre Blier, Larry Culpepper, Rakesh Jain, George I Papakostas, Michael E Thase. An overview of vortioxetine. The Journal of clinical psychiatry. 2014 Dec; 75(12):1411-8. doi: 10.4088/jcp.14027ah1. [PMID: 25551236]
  • Johan Areberg, Kamilla B Petersen, Grace Chen, Himanshu Naik. Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic & clinical pharmacology & toxicology. 2014 Dec; 115(6):552-9. doi: 10.1111/bcpt.12256. [PMID: 24766668]
  • Asres Berhan, Alex Barker. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC psychiatry. 2014 Sep; 14(?):276. doi: 10.1186/s12888-014-0276-x. [PMID: 25260373]
  • Grace Chen, Ronald Lee, Astrid-Maria Højer, Jeppe Klint Buchbjerg, Michael Serenko, Zhen Zhao. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clinical drug investigation. 2013 Oct; 33(10):727-36. doi: 10.1007/s40261-013-0117-6. [PMID: 23975654]
  • Per Stenkrona, Christer Halldin, Johan Lundberg. 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2013 Oct; 23(10):1190-8. doi: 10.1016/j.euroneuro.2013.01.002. [PMID: 23428337]
  • Cécile Bétry, Alan L Pehrson, Adeline Etiévant, Bjarke Ebert, Connie Sánchez, Nasser Haddjeri. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. The international journal of neuropsychopharmacology. 2013 Jun; 16(5):1115-27. doi: 10.1017/s1461145712001058. [PMID: 23089374]
  • Johan Areberg, Birgitte Søgaard, Astrid-Maria Højer. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic & clinical pharmacology & toxicology. 2012 Sep; 111(3):198-205. doi: 10.1111/j.1742-7843.2012.00886.x. [PMID: 22448783]
  • Johan Areberg, Michael Luntang-Jensen, Birgitte Søgaard, Dorrit Ø Nilausen. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic & clinical pharmacology & toxicology. 2012 Apr; 110(4):401-4. doi: 10.1111/j.1742-7843.2011.00810.x. [PMID: 21985522]
  • A Mørk, A Pehrson, L T Brennum, S Møller Nielsen, H Zhong, A B Lassen, S Miller, L Westrich, N J Boyle, C Sánchez, C W Fischer, N Liebenberg, G Wegener, C Bundgaard, S Hogg, B Bang-Andersen, T Bryan Stensbøl. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. The Journal of pharmacology and experimental therapeutics. 2012 Mar; 340(3):666-75. doi: 10.1124/jpet.111.189068. [PMID: 22171087]
  • Henriette Kold Uldam, Martin Juhl, Henrik Pedersen, Lars Dalgaard. Biosynthesis and identification of an N-oxide/N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004. Drug metabolism and disposition: the biological fate of chemicals. 2011 Dec; 39(12):2264-74. doi: 10.1124/dmd.111.040428. [PMID: 21896789]
  • Benny Bang-Andersen, Thomas Ruhland, Morten Jørgensen, Garrick Smith, Kristen Frederiksen, Klaus Gjervig Jensen, Huailing Zhong, Søren Møller Nielsen, Sandra Hogg, Arne Mørk, Tine Bryan Stensbøl. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. Journal of medicinal chemistry. 2011 May; 54(9):3206-21. doi: 10.1021/jm101459g. [PMID: 21486038]